TGFBI, a transforming growth factor β-induced extracellular matrix protein, circulates at a level of~300 ng/ml in humans and modulates several integrin-mediated cellular functions. The protein contains an N-terminal EMI domain, four consecutive FAS1 domains, and the RGD motif. Each FAS1 domain and the RGD motif have been known to interact with avb3 integrin. Here, we found that the binding affinity (K d ) of TGFBI for αvβ3 integrin was approximately 3.8 × 10
Introduction
Angiogenesis, the formation of new capillaries from preexisting blood vessels, is central to tumor growth and metastasis. This process is a key early event in tumor progression and is essential for the expansion of solid tumors. Thus, targeting the tumor vasculature limits growth and represents an effective therapy for tumor suppression [1] [2] [3] [4] .
Endogenous angiogenic inhibitors are molecules that naturally circulate in the body and maintain anti-angiogenic activity, offering a physiological counterbalance for angiogenic factors [5, 6] . Among many angiogenic factors, integrins represent one of the main targets of endogenous angiogenic inhibitors. As an example, endostatin and tumstatin -proteolytic fragments derived from the extracellular matrix -interact with the integrin receptors, α5β1 and αvβ3, respectively, on endothelial cells, leading to alterations in intracellular signaling and anti-angiogenic effects [7] [8] [9] . Thrombospondin-1 (TSP-1), one of the first-identified endogenous matrix-derived angiogenic inhibitors, exerts anti-angiogenic activity as a full-length gene product. TSP-1 interacts with various molecules, including CD36, CD47, several growth factors and αvβ3 integrins, and regulates angiogenesis by inhibiting proliferation and migration and inducing apoptosis of endothelial cells [10, 11] .
In particular, αvβ3 integrins, which are highly expressed on activated tumor endothelial cells, are significantly involved in the proliferation and movement of vascular endothelial cells and play critical roles in tumor angiogenesis and growth [12, 13] . Functionally blocking αvβ3 integrins suppresses tumor angiogenesis, supporting the potential importance of these integrins in the angiogenic process [14] [15] [16] [17] .
TGFBI is a secretory protein induced by transforming growth factor-β (TGF-β) in a variety of cell types [18] [19] [20] [21] . The protein is composed of an N-terminal cysteine-rich domain (EMI), four consecutive repeats that share high homology with Drosophila fasciclin-1 (FAS1), and an RGD motif in the C-terminal region [22] . FAS1 domain-or RGD motifcontaining proteins, including TGFBI, participate in cell adhesion and migration via interactions with various integrins, including αvβ3 integrin [23] [24] [25] . Several studies have established that the anti-tumorigenic activity of TGFBI is markedly downregulated upon hypermethylation of promoter region of the corresponding gene in various tumor cell lines [26, 27] . Other recent investigations have shown that loss of TGFBI expression contributes to enhanced cell proliferation in association with mitotic spindle abnormalities, induction of a tumorigenic phenotype, and a higher frequency of spontaneous tumors [28, 29] .
We previously reported that the FAS1 domain of TGFBI exerts anti-angiogenic activity in vitro and in vivo through direct interactions with αvβ3 integrin, leading to tumor inhibition [30, 31] . However, it is not known whether the FAS1 domain, a 20-kDa proteolytic fragment of TGFBI, is generated endogenously; moreover, the effects of the intact, naturally circulating form of TGFBI on tumor angiogenesis have not been established. Several studies have shown that the introduction of the multimeric RGD peptide resulted in increased αvβ3 integrin-binding affinity and specificity compared with those of RGD monomer [32, 33] . TGFBI is composed of multimeric domains -four FAS1 domains and RGD motif -which interact with αvβ3 integrin. The strong antiangiogenic activity and improved therapeutic effect of TGFBI protein with high affinity and specificity for αvβ3 integrin can therefore be anticipated. Given that full-length TGFBI containing four FAS1 domains and one RGD motif circulates at a level of approximately 300 ng/ml in humans, we hypothesized that regulation of the physiological level of the protein is sufficient to exert potent anti-tumor growth activity via inhibition of tumor angiogenesis.
Several endogenous angiogenic inhibitors have been identified and subsequently developed as drugs that exhibit sufficient safety and lower toxicity compared with conventional chemotherapeutic agents. However, the use of endogenous angiogenic inhibitors has limitations in human cancer treatment. Therefore, further studies are required to improve our understanding of the mechanisms underlying the anti-angiogenic activity of endogenous inhibitors and develop optimal therapeutic candidates for cancer. In this study, we show that the cooperative action of the four FAS1 domains and RGD motif of TGFBI contributes to enhanced binding affinity for αvβ3 integrin and inhibitory effects of tumor angiogenesis and growth.
Materials and methods

Production of recombinant proteins
Recombinant TGFBI protein and forth FAS1 domain, comprising amino acid residues 68-653 and 498-637 of human TGFBI, were cloned into pET29b(+) (Novagen; Madison, WI). The deletion mutants of TGFBI, TGFBI_del. EMI, TGFBI_del. RGD, TGFBI_del. EMI RGD, FAS1_D12, FAS1_34, and EMI, were cloned into pET29b(+) and translated amino acid residues 133-653, 16-640, 133-640, 129-377, 368-637, and 16-105 of human TGFBI, respectively. Each of the recombinant proteins was induced and purified as described previously [19, 24] . Endotoxin was removed by phase separation with Triton X-114 [34] and the levels in the final preparations were dropped to below 0.1 EU/ml as measured by Limulus Amebocyte Lysate assay (Sigma-Aldrich).
Western blot analysis of extracts from various cell lines using integrin β3 antibody
The cultured cells were lysed in a cell lysis buffer (20 mM Tris, pH 8.0, 137 mM NaCl, 2 mM EDTA, 1% Triton X-100, a protease inhibitor cocktail (Sigma) and 10% glycerol) and subjected to SDS-polyacrylamide gel electrophoresis. The proteins were then transferred to nitrocellulose membranes (Amersham Pharmacia Biotech, Uppsala, Sweden), which were blocked for 1 h in TBS-T (50 mM Tris-HCl, 150 mM NaCl, and 0.05% Tween 20) containing 5% non-fat dry milk. The membranes were then incubated overnight with β3 antibodies (Cell signaling Technology, Inc.) at 4°C and washed three times in TBS-T. The proteins were visualized using an enhanced chemiluminescence reagent (Pierce, Rockford, IL) and signal detection was performed with an image analyzer (LAS-2000, Fuji, Tokyo, Japan).
In vitro assays for endothelial cell functions related to angiogenesis
In vitro assay was done as described previously [30, 35] . HUVECs (3 × 10 4 cells/100 μl) were pre-incubated with or without the indicated concentration of the TGFBI or FAS1 domain for 40 min at 37°C. For cell adhesion assay, pre-incubated cells were added to each well of 96-well ELISA plates (Costar, Corning, Inc., NY), which were coated overnight at 4°C with 5 μg/ml of vitronectin (R&D Systems) and blocked for 1 h at room temperature with PBS containing 2% bovine serum albumin (BSA). After incubation for 5 to 10 min at 37°C, unattached cells were removed by rinsing with PBS. Attached cells were incubated for 1 h at 37°C in 50 mM citrate buffer (pH 5.0) containing 3.75 mM p-nitrophenyl-N-acetyl-beta-D-glucosaminide (hexosaminidase substrate) and 0.25% Triton X-100. Enzyme activity was blocked by adding 50 mM glycine buffer (pH 10.4) containing 5 mM EDTA, and the absorbance was measured at 405 nM using a Sunrise Basic microplate reader (Tecan). For cell migration assay, pre-incubated cells were added to the upper compartment of Transwell plates (8 μM pore size, Costar, Cambridge, MA), in which the undersurface of the filter membrane was coated with 5 μg/ml of vitronectin for 2 h at room temperature and blocked for 1 h at room temperature with 2% BSA. Cells were allowed to migrate for 4 h at 37°C. The filters were fixed with 4% PFA and stained with crystal violet, and non-migrating cells on the upper surface of the filter were removed by wiping with a cotton swab. The extent of cell migration was determined by light microscopy and counting was done in four randomly selected fields at 200× magnifications. For tube formation assay, pre-incubated cells were seeded on the surface of Matrigel (Chemicon, International Inc., Temecula, CA), which was added (100 μl) into each well of a 96-well plate and polymerized for 30 min at 37°C. Cells were incubated for 6 h at 37°C. The cells were photographed, and branch points from four random fields at 200× magnifications were counted and averaged.
Antibody production
Anti-human TGFBI monoclonal antibody was produced in BALB/c mouse by repeated immunizations with recombinant human TGFBI protein corresponding to amino acids 498-637 produced in E. coli followed by hybridoma development. A consistently positive hybridoma clone (Clone 18B3) was used to produce ascites fluid, as described by Harlow and Lane [36] . Ascites fluid was clarified by centrifugation to remove the lipid layer and the cell pellet and further purified by Protein A affinity chromatography (Amersham Biosciences, Uppsala, Sweden) according to the manufacturer's protocol. The specificity of the anti-human TGFBI antibody was tested by Western blotting and immunoprecipitation. This antibody did not cross-react with mouse TGFBI.
Binding assay
HUVECs were grown to 80% confluence in 96-well plates, washed twice with PBS, and incubated with elevated concentrations of each protein for 1 h at room temperature. Cell binding of each protein was detected by His-probe-HRP antibody (Santa Cruz Biotechnology, Inc.). In saturation binding assays, αvβ3 integrin or BSA, which was immobilized on 96-well plates, was incubated with various concentrations of each protein which was diluted in a binding buffer, containing 25 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.05% Tween-20, 1 mM MnCl 2 , 1 mM MgCl 2 and 0.1 mM CaCl 2 , for 2 h at room temperature and non-bound proteins were removed by washing with PBS. The total binding of each protein for αvβ3 integrin was detected by His-probe-HRP antibody and quantified by measuring horseradish peroxidase activity. Enzyme activity was stopped by adding 8 N H 2 SO 4 buffer and measured using a Sunrise Basic microplate reader (Tecan) at 490 nM. The affinity of each protein for HUVECs was calculated by Scatchard analysis. Specific binding of each protein for αvβ3 integrin was calculated as the difference between total and nonspecific binding, which was measured in every experiment by determining the binding of each protein to BSA-coated wells. The affinity of each protein for αvβ3 integrin was calculated using Sigma plot 10.0 software. All data represent the average of duplicate measurements. All assays were repeated at least three times yielding identical results.
Homology modeling of FAS_D12 and FAS_D34
The homology models of FAS_D12 and D34 were built using the program SWISS-MODEL (http://swissmodel.expasy.org). The structures were further refined using the MODELLER program (v9.2) (http://www.salilab.org/modeller) [37, 38] . The homology models were validated by a Ramachandran plot 2.0, indicating no disallowed conformations (http://dicsoft1.physics.iisc.ernet.in/rp/select.html). The surface electrostatic potential was calculated using DelPhi calculation and displayed using Pymol (http://www.pymol.org).
In vivo tumor assay
Male BALB/c nude mice (5-6 weeks old) were implanted with 1 × 10 6 B16F10 cells or LLC cells into the flank subcutaneously and tumor growth and neovascularization after systemic treatment with exogenous FAS1 domain (5 μM) or TGFBI (50 nM or 10 nM) were monitored. Experimental groups were i.p. injected every day for 17-22 days with the indicated concentration of FAS1 domain or TGFBI in a total volume of 0.1 ml.
Immunostaining
3 μM paraffin sections of B16F10 tumor were incubated with a rat anti-mouse CD31 antibody (BD Biosciences) at room temperature for 1 h. Subsequently, they were washed with PBS and incubated with Alexa Fluor 594 conjugated secondary antibody (Invitrogen). Sections were counterstained with DAPI. Intratumoral microvessel density was counted at 200× magnifications in a blinded fashion for 4 separate fields and averaged. Each group consisted of six or eight tumor tissues. Frozen sections (5 μM or 20 μM) of LLC tumors receiving free Alexa Fluor 488 dye or Alexa Fluor 488 dye labeled TGFBI, obtained with a cryostat, were dried, fixed with ice-cold acetone, washed in PBS, then incubated with primary antibodies recognizing the following epitopes: CD31 and CD61 (BD Biosciences), all at 1:50 dilution. The sections were incubated with the appropriate fluorescently conjugated secondary antibody, 1:300 dilution, including anti-rat Alexa Fluor 488, 594, or 647 conjugated (Invitrogen) antibodies and anti-Armenian hamster IgG Rhodamine conjugated (Abcam) antibody. Images were acquired using an Olympus BX51 microscope driven by SPOT Advanced version 4.0.9 imaging software (Diagnostic Instruments) and a Zeiss Axiovert 200M microscope (Zeiss LSM 5, Carl Zeiss Inc., Germany). Confocal Z-stack images were created at 1.2 μM intervals throughout the 20 μM of the sections.
Measurement of half-life of TGFBI in mouse blood
TGFBI was labeled with the green fluorescent dye, FNG-456 (DKC Corp., Incheon, Korea). After anesthesia, the B16F10 tumor bearing mouse received a dose of 5 mg/kg of FNG-456 labeled TGFBI in 200 μl of PBS via the mouse tail vein. At time intervals of 2-15 min after injection, blood was collected from the right ventricle of heart. The plasma of each mouse was obtained by centrifugation of blood and the plasma samples were analyzed by ELISA assay. Each experiment consisted of 4 mice. To determine the plasma concentration of TGFBI, we developed and validated an ELISA using human TGFBI antibody (Clone 18B3). The levels of FNG-456 labeled TGFBI were determined by measuring the emission intensity at 520 nM. The level of plasma fluorescence was plotted against time and the half-life was calculated with the PK Functions software.
Micro-CT angiography
After the LLC tumor bearing mice were euthanized and injected i.p. with 100 μl of heparin 10 min before tumor sacrifice. The thoracic cavity was opened, an incision was made in the right atrium of the heart, and a polyethylene cannula (23 G × 3/4″) was passed through the left ventricle. A 24 ml solution of 0.1 mM sodium nitroprusside in PBS was perfused at a rate of 6 ml/min to provide a state of maximum vasodilatation and to remove blood. Mice were then perfused with 24 ml of MICROFIL (MV-122, Carver), a commercially available lead chromate latex, at a rate of 2 ml/min. The infused latex mixture was allowed to polymerize at room temperature for 1 h before dissection of tumor tissues. Dissected tumors were immersed in 4% PFA and then placed in a mixture of water and glycerin. The tumor vasculature images were acquired from a Skyscan 1076 (Skyscan N.V., Belgium) X-ray micro-CT system at a voxel resolution of 18 × 18 × 18 μM. Scanning parameters were set at a voltage of 45 kV, a current of 180 μA, aluminum filter with 0.5 mm thickness, an exposure time of 590 ms and a rotation step of 0.5°. Three dimensional models of vessel and tissue were reconstructed from acquired cross-section images by Mimics 13.1 (Materialise NV, Belgium), and their volumes were measured. The vessel volume divided by the tissue volume was termed the vessel volume fraction.
In vivo tumor imaging
TGFBI was labeled to a 4.7:1 incorporated dye:protein ratio with the near-infrared dye, Cy7.5-NHS (GE Healthcare, UK). Cy7.5-labeled TGFBI of 100 μl was injected intraperitoneally to LLC tumor bearing mouse. An equivalent amount of free dye was administered as a control. Mice were imaged using the eXplore Optix small animal molecular imaging unit (ART Inc., Canada) at 1 and 24 h after conjugate administration. Analysis of images was performed using eXplore Optix Analysis Workstation software; a region of interest was manually selected and the signal intensity was calculated as concentration.
Statistical analysis
All values are expressed as the means ± SD. The statistical significance of differences between the experimental and control groups was evaluated using analysis of variance (ANOVA). A p-value of b0.05 was considered to be statistically significant, and is indicated by an asterisk over the value.
Results
TGFBI inhibits tumor growth and angiogenesis
We anticipated that the anti-angiogenic activity of TGFBI in vitro and in vivo would be higher than that of a single FAS1 domain, owing to the presence of multiple FAS1 domains and RGD motif [30, 31] . To test this hypothesis, we examined the in vitro anti-angiogenic activities of TGFBI, measuring inhibition of cell adhesion, migration, and tube formation compared with a single FAS1 domain. Vitronectin is a ligand of the αvβ3 integrin and the ligation between the two induces cellular adhesion and migration to the vitronectin. To determine whether TGFBI can inhibit vitronectin-induced cell adhesion, we performed a cell adhesion assay using human umbilical vein endothelial cells (HUVECs). The expression level of αvβ3 integrin on HUVECs was observed by Western blot (Supplementary Fig. 1A ). As shown in Fig. 1A and B, TGFBI induced a concentration-dependent inhibition of cell adhesion to vitronectin, with an IC 50 (50% inhibitory concentration) value of 105.7 nM, which was 100-fold lower than that observed with the FAS1 domain alone (9.5 μM). Several types of angiogenic inhibitors have been reported to display a biphasic, bell-shaped or U-shaped curve of efficacy [39] [40] [41] . We investigated the effect of TGFBI in the range from 5 nM (340 ng/ml) to 8 μM (544 μg/ml), but no doses of biphasic response were observed on HUVEC adhesion to vitronectin ( Supplementary Fig. 1C ). To determine whether these effects of TGFBI were αvβ3 integrin-dependent, we performed a cell adhesion assay using HEK293 cell lines stably overexpressing β3 and β5 integrins ( Supplementary Fig. 1B ). TGFBI treatment resulted in inhibition of adhesion in β3/HEK293 cells but not in β5/HEK293 cells (Fig. 1C) . Analogous to its effects on cell adhesion, TGFBI suppressed endothelial cell migration towards vitronectin in a concentration-dependent manner. Moreover, 50 nM TGFBI displayed higher inhibitory activity than 5 μM FAS1 domain (Fig. 1D, Supplementary Fig. 2A ). To determine whether endothelial cell migration towards vitronectin is suppressed by treatment of TGFBI, we generated a function blocking antibody against human TGFBI and examined its effects on endothelial cell migration. TGFBI inhibited vitronectin-induced HUVEC migration on Boyden chambers coated with vitronectin and this inhibition was reversed by treatment with the functional blocking monoclonal antibody against TGFBI (Fig. 1E, Supplementary Fig. 2B ). Similar results were obtained in endothelial tube-formation assays (Fig. 1F, Supplementary Fig. 2C ), in which 50 nM TGFBI showed activity comparable to that of 5 μM FAS1 domain.
We next examined whether the anti-angiogenic effects of TGFBI in vitro were correlated with in vivo activities using a B16F10 murine melanoma tumor xenograft model in BALB/c nude mice. Daily administration of 5 μM FAS1_D4 (10 mg/kg) and 50 nM TGFBI (340 μg/kg), which is a 100-fold lower molar dose, exerted similar tumor growth-suppressing activities. Additionally, treatment with 10 nM TGFBI (68 μg/kg) induced a comparable inhibitory effect, indicative of the significantly stronger tumor growth-inhibitory activity of the full-length protein compared to that of the FAS1 domain alone ( Fig. 2A) . To determine whether the reduction in tumor size coincided with decreased neovascularization, we quantified the microvessel densities of six representative tumors after immunostaining with an anti-CD31 antibody. As shown in Fig. 2B and C, blood vessel numbers in all three groups -50 nM TGFBI, 10 nM TGFBI and 5 μM FAS1_D4 -were decreased to a similar extent compared to the control (PBS) group.
These results collectively show that the anti-angiogenic activity of TGFBI is approximately 100-fold greater than that of the FAS1 domain alone, indicating that anti-angiogenic activity is enhanced by the cooperative conformation of FAS1 domains and the RGD motif.
To characterize the pharmacokinetics of TGFBI, B16F10 tumor bearing mice were administrated a single bolus intravenous injection of fluorescence-labeled TGFBI at a dose of 5 mg/kg and serial plasma samples were subsequently obtained at 2, 15, 30, 45, 60, and 120 min post-injection. The single dose pharmacokinetic pattern is shown graphically in Fig. 2D . TGFBI was rapidly removed from the plasma compartment in mice, exhibiting a terminal half-life of 20.3 min.
TGFBI binds to HUVECs and αvβ3 integrin with high affinity
Previously, we reported that the FAS1 domain inhibits angiogenesis via αvβ3 integrin [31] . To establish whether the more potent anti-angiogenic activity of TGFBI is due to higher binding affinity to αvβ3 integrin, we estimated the binding affinity to human umbilical vein endothelial cells (HUVECs) and αvβ3 integrin. Binding of TGFBI and FAS1 domain to HUVECs was specific and hyperbolic. A Scatchard analysis of the binding curve revealed a single binding site for TGFBI with a K d value of 278 nM, compared to a K d value for the FAS1 domain of 26.4 μM. These data indicate that TGFBI binds HUVECs with 100-fold stronger affinity than does the FAS1 domain alone (Fig. 3A,  B) .
We further evaluated the binding affinity of TGFBI and FAS1 domains to αvβ3 integrin. Binding of TGFBI was integrin-concentration dependent ( Supplementary Fig. 3 ) and specific at the concentrations of αvβ3 (4 μg/ml) used for further binding analyses. Enzyme-linked immunosorbent assays (ELISAs) showed that TGFBI binding to αvβ3 integrin was concentration-dependent and hyperbolic. The K d values for TGFBI and FAS1 domain binding to αvβ3 integrin were 38.2 nM and 90 μM, respectively (Fig. 3C, D) . Interestingly, the binding affinity of TGFBI for αvβ3 integrin (38.2 nM) was 7.3-fold higher than that for HUVECs (278 nM), whereas that of FAS1 domain for αvβ3 integrin (90 μM) was 3.4-fold lower than that for HUVECs (26.4 μM). Our findings suggest that the potent anti-angiogenic activity of TGFBI is attributable to its high binding affinity for αvβ3 integrin.
High affinity TGFBI binding to αvβ3 integrin is mainly attributable to the four FAS1 domains and RGD motif
To identify the specific domains of TGFBI involved in αvβ3 integrin binding, we generated a series of deletion mutants (described in Fig. 4A ). Upon deletion of the RGD motif, the binding affinity of TGFBI for αvβ3 integrin was decreased by 8.5-fold (from 38 to 325 nM) and the maximum specific binding, B max , was reduced by half. Deletion of the EMI domain had only a slight effect on the binding affinity of TGFBI, suggesting that this region is not critical for interactions with αvβ3 integrin (Fig. 4B, D) . In vitro binding experiments additionally showed that the EMI domain did not specifically bind to αvβ3 integrin ( Supplementary Fig. 4 ). Next, we examined whether binding affinity of TGFBI for integrin is dependent on the number of FAS1 domains. We generated constructs incorporating different FAS1 combinations and numbers, specifically: FAS1_D1234, FAS1_D12, FAS1_D34, FAS1_D4 and FAS1_D4 [4n] [four repeats of FAS1_D4] (Fig. 4A) . All constructs were capable of interacting with αvβ3 integrin with different affinities and maximum binding capacities (Fig. 4C, D) . FAS1_D1234 protein, lacking the RGD motif and EMI domain, bound effectively to αvβ3 integrin with an affinity of 340 nM, indicating that the four repeats of the FAS1 domain coordinate with the RGD motif to achieve strong and specific binding to αvβ3 integrin. The number of FAS1 domain repeats appeared to affect binding affinity since two (FAS1_D12, FAS1_D34) or four repeats (FAS1_D1234, FAS1_D4 [4n] ) of FAS1 domain bound αvβ3 integrin with higher affinity than the single FAS1 domain, FAS1_D4. The domain arrangement of FAS1 repeats appeared more critical for binding, despite the fact that each FAS1 domain shares conserved sequence motifs. Natural repeats of the FAS1 domains of TGFBI (FAS1_D1234) showed 12-fold higher affinity than four artificially generated repeats of the FAS1 domain (FAS1_D4 [4n] ). Furthermore, upon deletion of FAS1 domains 1 and 2, affinity was decreased by 255-fold to 86.84 μM, whereas deletion of FAS1 domains 3 and 4 only decreased binding affinity by 2.1-fold to 715 nM, implying that FAS1_D12 domains play a critical role in binding to αvβ3 integrin. To explain the differential binding abilities of the FAS1 domain constructs, in particular, the marked discrepancy between FAS1_D12 and FAS1_D34, we generated three-dimensional (3D) structural models of FAS1_D12 and FAS1_D34 based on sequence homology to the crystal structure of fasciclin (PDB code, 1o70; Fig. 4E ). The initial models were obtained from the Swiss-Prot modeling server and were refined using the MODELLER program (v9.2; Univ. of San Francisco) [37, 38] . The 3D model structures revealed several interesting features. In a single FAS1 domain, 18 amino acids centered on conserved YH residues (YH18) and the C-terminal NKDIL/EPDIM sequence appeared to be critical for cellular activity via interaction with integrins [24, 30, 35] . The two binding motifs identified, YH18 from FAS1_D1 or FAS1_D3, and NKDIL/ EPDIM sequences from FAS1_D2 or FAS1_D4, are located in close proximity and likely form a critical binding surface for αvβ3 integrin in the double FAS1 domain constructs, which may explain why the affinity of double-domain constructs is stronger than that of the single FAS1 domain. In addition, the charge distribution of the binding surface of FAS1_D12 was distinct from that of FAS1_D34. The FAS1_D12 binding surface, with its exposed acidic and hydrophobic moiety, may form a more stable complex with αvβ3 integrin than does that of FAS1_D34, which has a basic moiety and is less hydrophobic.
TGFBI localizes to the tumor site and inhibits LLC tumor growth
To establish whether TGFBI also suppresses tumor growth in a different tumor model, we transplanted BALB/c nude mice with LLC tumor cells. TGFBI treatment reduced the growth of LLC tumors in a similar manner to that observed in the B16F10 xenograft model (Fig. 5A) . TGFBI treatment delayed tumor growth by 5 days compared with PBS. To further establish the role of TGFBI in tumor angiogenesis, we examined the vasculature of LLC tumors from mice treated with TGFBI or PBS using micro-CT (computed tomography), which generates a comprehensive image of the vasculature of the entire tumor, thus overcoming the limitations of histologic analyses. A representative vessel image of the entire tumor mass is shown in Fig. 5B . Consistent with immunohistochemical findings (Fig. 2B) , TGFBI treatment significantly suppressed tumor angiogenesis. In particular, we observed a 6-fold reduction in total vessel volume in TGFBI-treated mice relative to PBS-treated mice (Fig. 5C ). Blood vessel density (vascular volume/tumor volume) was also reduced by 2.2-fold in the TGFBI-treated group (Fig. 5D) . Micro-CT data support the hypothesis that suppression of tumor growth in TGFBI-treated mice is mainly due to inhibition of angiogenesis.
To determine the localization of injected TGFBI in vivo, we performed in vivo optical imaging studies on LLC tumor-bearing mice. TGFBI labeled with the near-infrared dye Cy7.5 or an equivalent amount of free dye (control) was injected intraperitoneally into BALB/ c nude mice bearing subcutaneous LLC tumors. Near-infrared optical images revealed that TGFBI labeled with the Cy7.5 fluorescent signal localized to the tumor site 1 h after injection with 5-fold greater intensity than control (Fig. 6A ). This localized signal was maintained up to 24 h after injection. To establish the microscopic localization of TGFBI in tumors, we injected a conjugate of TGFBI with Alexa Fluor 488 dye into LLC tumor-bearing mice via a single intraperitoneal injection 1 h prior to sacrifice. CD31 immunostaining of tumor tissue slides allowed visualization of the tumor vasculature. Immunostaining for β3 integrin, conducted to determine the specific ability of TGFBI to bind αvβ3 integrin, revealed protein localization at the luminal surface of CD31-positive tumor blood vessels (Fig. 6B) . No signal was detected in the tumor tissue of control mice receiving free Alexa Fluor 488 dye. Assessment of β3 integrin expression (αvβ3) on LLC tumor tissue confirmed that the majority of CD31-positive tumor blood vessels expressed αvβ3 (Supplementary Fig. 5 ). Moreover, TGFBI specifically localized to β3 integrin (αvβ3)-expressing tumor blood vessels (Fig. 6C) . 
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Discussion
A previous study by our group showed that exogenously administered FAS1 domain exerts anti-tumorigenic activity via inhibition of angiogenesis through interactions with αvβ3 integrin [31] . In this study, we further demonstrated that circulating TGFBI containing FAS1 domains functions as a strong endogenous regulator of pathologic angiogenesis through interactions with αvβ3 integrin. TGFBI exhibited significantly more potent anti-tumorigenic activity than did a single FAS1 domain. Daily treatment with TGFBI at 340 μg/kg -a 30-fold lower mass (and a 100-fold lower molar concentration: 50 nM vs. 5 μM) than the 10 mg/kg dose of FAS1 domain alone -led to marked suppression of tumor growth. Each FAS1 domain of TGFBI bears a YH18 motif, which is known to interact with αvβ3 integrin and stimulate anti-angiogenic activity. However, the YH18 motif and FAS1 domain only exhibited anti-angiogenic activity at high concentrations (up to 100 μM and 5 μM, respectively), indicating that these sequences are 1000-and 100-fold less active than full-length TGFBI.
The superior anti-angiogenic activity of TGFBI was confirmed by in vitro cell-adhesion, migration, and tube-formation assays. In particular, TGFBI strongly suppressed HUVEC migration (up to 60%) at a 1000-fold lower concentration than did the FAS1 domain alone.
Three main characteristics may explain the potent anti-angiogenic activity of TGFBI. First, TGFBI incorporates multiple (four) FAS1 domains and the RGD motif, which provides efficient binding to αvβ3 integrin. Second, the four FAS1 domain repeats provide not only additive but also synergistic effects through a domain arrangement that allows for optimal binding. Third, TGFBI inhibits tumor angiogenesis via specific interactions with αvβ3 integrin in vascular endothelial cells.
Several studies have demonstrated increased specific binding affinity or activity of proteins with multimeric binding domains compared with their monomeric counterparts [32] . In this case, TGFBI bound strongly to HUVECs and αvβ3 integrin, exhibiting 2300-fold higher affinity than the single FAS1 domain. We propose that these properties of TGFBI reflect the combined effects of the four FAS1 domains and RGD motif on the αvβ3 integrin target. The RGD motif appears to play a critical role in binding, in view of the finding that the binding affinity and capacity (B max ) of TGFBI were significantly decreased upon the deletion of this sequence. Although TGFBI consists of multiple αvβ3 integrin binding motifs, the binding reaction possibly involves a simple 1:1 stoichiometry, since its binding graph pattern is specific and hyperbolic. The coordinating interactions of FAS1 domains and the RGD motif are supported by our previous findings that the FAS1 domain competes with an RGD-containing peptide and inhibits endothelial cell adhesion and migration in an RGD-dependent manner [24, 31] .
In fact, RGD-deleted TGFBI constructs (FAS1_D1234) retained considerable binding affinity. We propose that the four FAS1 domain repeats confer synergistic effects by virtue of their domain arrangement, producing optimal binding to αvβ3 integrin. This theory is supported by two observations: 1) FAS1_D4 [4n], containing four artificial repeats of FAS1_D4, displayed 12.3-fold lower affinity than the natural repeat, FAS1_D1234, but greater binding affinity than the single FAS1_D4 domain, indicating that the high binding affinity of the four FAS1 domain αvβ3 integrin inhibit tumor growth by affecting both tumor cells and tumor vascular endothelial cells. Moreover, several studies have reported crosstalk between αvβ3 integrin and VEGFR-2, and shown that inhibition of αvβ3, but not β5, suppresses VEGFR-2 signaling by VEGF [42] . Therefore, αvβ3 integrin is an attractive therapeutic target for anti-tumor therapy. Our in vivo and in vitro experiments showed that TGFBI is strongly bound to vascular endothelial cells expressing αvβ3 integrins. Antagonists of αvβ3 integrin, including the humanized monoclonal antibody, Vitaxin, and the RGD mimetic, Cilengitide, currently undergoing clinical trials, have been reported to extend cancer patient survival with minimal side effects [43, 44] . However, mouse studies by Reynolds et al. showed that continuous treatment with low concentrations of RGD mimetics paradoxically stimulates tumor growth and angiogenesis via enhancement of VEGFR-2 and β3 integrin recycling [39] . Furthermore, the increased VEGF-mediated angiogenesis observed in β3 integrin-deficient mice is caused by a compensatory increase in VEGFR-2, indicating that β3 integrin is involved in tumor angiogenesis [45] . In this respect, the local balance between endogenous angiogenic stimulator and inhibitor levels is critical for tumor angiogenesis, and thus the physiological blood concentrations of these endogenous angiogenic inhibitors are of significance. Indeed, tumor growth in endostatin transgenic mice displaying a 1.6-fold increase in circulating endostatin levels is 3-fold slower than that in control mice. Additionally, in tumstatin/TSP-1 double-knockout mice, tumor growth is 2-fold faster compared with that in single tumstatin-or TSP-1-deficient mice [46] . Our results showed that it was possible to inhibit tumor growth by exogenous administration of TGFBI to redress the imbalance between angiogenic stimulator and inhibitor. Consistent with our findings, Zhang et al. reported increased cell proliferation and incidence of spontaneous tumors upon loss of TGFBI expression in TGFBI −/− mice [29] . And, recent studies using lung and breast cancer cell lines show that TGFBI restrains the metastatic potential of these cells, supporting the tumor suppressor function of TGFBI [47] . However, contrary evidence from other groups was presented that TGFBI increased the metastatic ability of colon and ovarian cancer cell lines [48, 49] . These opposing effects of TGFBI suggest the possibility that TGFBI functions to be different, depending on the cell type and the concentration of TGFBI, and highlights the importance of the tumor microenvironment for TGFBI function.
In fact, the significance of the therapeutic concentration of antiangiogenic molecules has been reported through various papers. It shows the biphasic dose-responses, bell-shaped or U-shaped doseresponse, are observed in many other anti-angiogenic molecules including RGD-mimetic integrin inhibitors, endostatin and TSP-1 [39] [40] [41] . We investigated the effect of TGFBI in the range from 5 nM (340 ng/ml) to 8 μM (544 μg/ml), which is a 1600-fold higher dose, but no doses of biphasic response were observed in the in vitro assay. Additional studies expanding to more types of cell lines and in vivo tumor models for the biphasic dose-response studies of TGFBI is required.
Previously, TGFBI expression was studied by immunohistochemistry in 130 primary human lung carcinomas and 192 cases of breast tumors [50, 51] . The results indicated a decrease in TGFBI expression from benign tissues to carcinomas. However, contrary results were also reported. Increased concentration of TGFBI was observed in both serum and urine of the bladder carcinoma patients [52] . Recently, Chang et al. reported that TGFBI has been confirmed to be overexpressed in pancreatic cancer tissues, but not the serum levels, and not statistically correlated with age, gender, histological grade, and overall tumor stage [53] . These results can be interpreted that a comparison of the relative expression level with other angiogenic stimulators is more meaningful than the simple quantification of TGFBI level in tumor microenvironment, offering a physiological counterbalance for angiogenic stimulators. Therefore, it is necessary to consider both the tumor cell type and microenvironment when treating with TGFBI for tumor therapy.
In summary, we have demonstrated that circulating TGFBI, a multi-FAS1 domain protein containing the RGD motif, effectively inhibits vascular endothelial cell movement, tumor angiogenesis, and tumor growth through direct interactions with αvβ3 integrin. Our data highlight the importance of physiologically circulating TGFBI as an endogenous anti-angiogenic regulator that inhibits tumor growth.
Supplementary data to this article can be found online at http:// dx.doi.org/10.1016/j.bbamcr.2013.06.012.
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